nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—ABCB1—esophageal cancer	0.381	1	CbGaD
Fluvoxamine—CYP2C9—Capecitabine—esophageal cancer	0.0443	0.306	CbGbCtD
Fluvoxamine—CYP2B6—Cisplatin—esophageal cancer	0.0422	0.292	CbGbCtD
Fluvoxamine—CYP2C9—Cisplatin—esophageal cancer	0.0223	0.154	CbGbCtD
Fluvoxamine—ABCB1—Cisplatin—esophageal cancer	0.0216	0.15	CbGbCtD
Fluvoxamine—ABCB1—Methotrexate—esophageal cancer	0.0141	0.0972	CbGbCtD
Fluvoxamine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000501	0.00198	CcSEcCtD
Fluvoxamine—Gastritis—Capecitabine—esophageal cancer	0.000493	0.00195	CcSEcCtD
Fluvoxamine—Muscular weakness—Capecitabine—esophageal cancer	0.000491	0.00194	CcSEcCtD
Fluvoxamine—Eye disorder—Cisplatin—esophageal cancer	0.000488	0.00193	CcSEcCtD
Fluvoxamine—Tinnitus—Cisplatin—esophageal cancer	0.000487	0.00192	CcSEcCtD
Fluvoxamine—Lymphadenopathy—Methotrexate—esophageal cancer	0.000486	0.00192	CcSEcCtD
Fluvoxamine—Cardiac disorder—Cisplatin—esophageal cancer	0.000485	0.00192	CcSEcCtD
Fluvoxamine—Abdominal distension—Capecitabine—esophageal cancer	0.000484	0.00191	CcSEcCtD
Fluvoxamine—Influenza—Capecitabine—esophageal cancer	0.000481	0.0019	CcSEcCtD
Fluvoxamine—Asthma—Capecitabine—esophageal cancer	0.000481	0.0019	CcSEcCtD
Fluvoxamine—Dysphagia—Capecitabine—esophageal cancer	0.000481	0.0019	CcSEcCtD
Fluvoxamine—Diabetes mellitus—Methotrexate—esophageal cancer	0.000476	0.00188	CcSEcCtD
Fluvoxamine—Photosensitivity—Methotrexate—esophageal cancer	0.000472	0.00186	CcSEcCtD
Fluvoxamine—Polyuria—Methotrexate—esophageal cancer	0.000472	0.00186	CcSEcCtD
Fluvoxamine—Angina pectoris—Capecitabine—esophageal cancer	0.000469	0.00185	CcSEcCtD
Fluvoxamine—Sweating increased—Capecitabine—esophageal cancer	0.000469	0.00185	CcSEcCtD
Fluvoxamine—Arrhythmia—Cisplatin—esophageal cancer	0.000467	0.00184	CcSEcCtD
Fluvoxamine—Bronchitis—Capecitabine—esophageal cancer	0.000463	0.00183	CcSEcCtD
Fluvoxamine—Alopecia—Cisplatin—esophageal cancer	0.000462	0.00182	CcSEcCtD
Fluvoxamine—Abdominal discomfort—Capecitabine—esophageal cancer	0.000461	0.00182	CcSEcCtD
Fluvoxamine—Malnutrition—Cisplatin—esophageal cancer	0.000455	0.0018	CcSEcCtD
Fluvoxamine—Dysuria—Capecitabine—esophageal cancer	0.00045	0.00178	CcSEcCtD
Fluvoxamine—Renal failure acute—Methotrexate—esophageal cancer	0.000449	0.00177	CcSEcCtD
Fluvoxamine—Flatulence—Cisplatin—esophageal cancer	0.000448	0.00177	CcSEcCtD
Fluvoxamine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000447	0.00177	CcSEcCtD
Fluvoxamine—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000439	0.00174	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000439	0.00174	CcSEcCtD
Fluvoxamine—Weight increased—Capecitabine—esophageal cancer	0.000438	0.00173	CcSEcCtD
Fluvoxamine—Visual disturbance—Methotrexate—esophageal cancer	0.000437	0.00173	CcSEcCtD
Fluvoxamine—Muscle spasms—Cisplatin—esophageal cancer	0.000437	0.00173	CcSEcCtD
Fluvoxamine—Weight decreased—Capecitabine—esophageal cancer	0.000435	0.00172	CcSEcCtD
Fluvoxamine—Hyperglycaemia—Capecitabine—esophageal cancer	0.000434	0.00172	CcSEcCtD
Fluvoxamine—Pneumonia—Capecitabine—esophageal cancer	0.000432	0.00171	CcSEcCtD
Fluvoxamine—Vision blurred—Cisplatin—esophageal cancer	0.000429	0.00169	CcSEcCtD
Fluvoxamine—Depression—Capecitabine—esophageal cancer	0.000428	0.00169	CcSEcCtD
Fluvoxamine—Tremor—Cisplatin—esophageal cancer	0.000426	0.00168	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000425	0.00168	CcSEcCtD
Fluvoxamine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000423	0.00167	CcSEcCtD
Fluvoxamine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000423	0.00167	CcSEcCtD
Fluvoxamine—Lethargy—Methotrexate—esophageal cancer	0.000423	0.00167	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Cisplatin—esophageal cancer	0.000422	0.00167	CcSEcCtD
Fluvoxamine—Renal failure—Capecitabine—esophageal cancer	0.000422	0.00167	CcSEcCtD
Fluvoxamine—Myocardial infarction—Capecitabine—esophageal cancer	0.000421	0.00166	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000421	0.00166	CcSEcCtD
Fluvoxamine—Anaemia—Cisplatin—esophageal cancer	0.00042	0.00166	CcSEcCtD
Fluvoxamine—Stomatitis—Capecitabine—esophageal cancer	0.000418	0.00165	CcSEcCtD
Fluvoxamine—Jaundice—Capecitabine—esophageal cancer	0.000418	0.00165	CcSEcCtD
Fluvoxamine—Conjunctivitis—Capecitabine—esophageal cancer	0.000417	0.00165	CcSEcCtD
Fluvoxamine—Urinary tract infection—Capecitabine—esophageal cancer	0.000417	0.00165	CcSEcCtD
Fluvoxamine—Osteoarthritis—Methotrexate—esophageal cancer	0.000414	0.00164	CcSEcCtD
Fluvoxamine—Malaise—Cisplatin—esophageal cancer	0.00041	0.00162	CcSEcCtD
Fluvoxamine—Haematuria—Capecitabine—esophageal cancer	0.000409	0.00162	CcSEcCtD
Fluvoxamine—Leukopenia—Cisplatin—esophageal cancer	0.000407	0.00161	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000406	0.0016	CcSEcCtD
Fluvoxamine—Epistaxis—Capecitabine—esophageal cancer	0.000405	0.0016	CcSEcCtD
Fluvoxamine—Agranulocytosis—Capecitabine—esophageal cancer	0.0004	0.00158	CcSEcCtD
Fluvoxamine—Irritability—Methotrexate—esophageal cancer	0.000396	0.00156	CcSEcCtD
Fluvoxamine—Convulsion—Cisplatin—esophageal cancer	0.000394	0.00156	CcSEcCtD
Fluvoxamine—Mood swings—Methotrexate—esophageal cancer	0.000393	0.00155	CcSEcCtD
Fluvoxamine—Bradycardia—Capecitabine—esophageal cancer	0.000392	0.00155	CcSEcCtD
Fluvoxamine—Ataxia—Methotrexate—esophageal cancer	0.00039	0.00154	CcSEcCtD
Fluvoxamine—Myalgia—Cisplatin—esophageal cancer	0.000387	0.00153	CcSEcCtD
Fluvoxamine—Haemoglobin—Capecitabine—esophageal cancer	0.000387	0.00153	CcSEcCtD
Fluvoxamine—Rhinitis—Capecitabine—esophageal cancer	0.000386	0.00153	CcSEcCtD
Fluvoxamine—Anxiety—Cisplatin—esophageal cancer	0.000386	0.00152	CcSEcCtD
Fluvoxamine—Haemorrhage—Capecitabine—esophageal cancer	0.000385	0.00152	CcSEcCtD
Fluvoxamine—Hepatitis—Capecitabine—esophageal cancer	0.000385	0.00152	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Capecitabine—esophageal cancer	0.000383	0.00151	CcSEcCtD
Fluvoxamine—Liver function test abnormal—Methotrexate—esophageal cancer	0.000383	0.00151	CcSEcCtD
Fluvoxamine—Discomfort—Cisplatin—esophageal cancer	0.000383	0.00151	CcSEcCtD
Fluvoxamine—Pharyngitis—Capecitabine—esophageal cancer	0.000382	0.00151	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Capecitabine—esophageal cancer	0.00038	0.0015	CcSEcCtD
Fluvoxamine—Oedema peripheral—Capecitabine—esophageal cancer	0.000379	0.0015	CcSEcCtD
Fluvoxamine—Urethral disorder—Capecitabine—esophageal cancer	0.000378	0.00149	CcSEcCtD
Fluvoxamine—Breast disorder—Methotrexate—esophageal cancer	0.000375	0.00148	CcSEcCtD
Fluvoxamine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000373	0.00147	CcSEcCtD
Fluvoxamine—Oedema—Cisplatin—esophageal cancer	0.000371	0.00147	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Cisplatin—esophageal cancer	0.000371	0.00147	CcSEcCtD
Fluvoxamine—Visual impairment—Capecitabine—esophageal cancer	0.000371	0.00147	CcSEcCtD
Fluvoxamine—Infection—Cisplatin—esophageal cancer	0.000369	0.00146	CcSEcCtD
Fluvoxamine—Erythema multiforme—Capecitabine—esophageal cancer	0.000364	0.00144	CcSEcCtD
Fluvoxamine—Nervous system disorder—Cisplatin—esophageal cancer	0.000364	0.00144	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Cisplatin—esophageal cancer	0.000363	0.00144	CcSEcCtD
Fluvoxamine—Tachycardia—Cisplatin—esophageal cancer	0.000362	0.00143	CcSEcCtD
Fluvoxamine—Eye disorder—Capecitabine—esophageal cancer	0.00036	0.00142	CcSEcCtD
Fluvoxamine—Tinnitus—Capecitabine—esophageal cancer	0.000359	0.00142	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000359	0.00142	CcSEcCtD
Fluvoxamine—Asthma—Methotrexate—esophageal cancer	0.000358	0.00142	CcSEcCtD
Fluvoxamine—Cardiac disorder—Capecitabine—esophageal cancer	0.000357	0.00141	CcSEcCtD
Fluvoxamine—Anorexia—Cisplatin—esophageal cancer	0.000354	0.0014	CcSEcCtD
Fluvoxamine—Pancreatitis—Methotrexate—esophageal cancer	0.000351	0.00139	CcSEcCtD
Fluvoxamine—Angiopathy—Capecitabine—esophageal cancer	0.000349	0.00138	CcSEcCtD
Fluvoxamine—Hypotension—Cisplatin—esophageal cancer	0.000347	0.00137	CcSEcCtD
Fluvoxamine—Chills—Capecitabine—esophageal cancer	0.000346	0.00137	CcSEcCtD
Fluvoxamine—Arrhythmia—Capecitabine—esophageal cancer	0.000344	0.00136	CcSEcCtD
Fluvoxamine—Abdominal discomfort—Methotrexate—esophageal cancer	0.000343	0.00136	CcSEcCtD
Fluvoxamine—Alopecia—Capecitabine—esophageal cancer	0.00034	0.00134	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000338	0.00134	CcSEcCtD
Fluvoxamine—Mental disorder—Capecitabine—esophageal cancer	0.000337	0.00133	CcSEcCtD
Fluvoxamine—Malnutrition—Capecitabine—esophageal cancer	0.000335	0.00132	CcSEcCtD
Fluvoxamine—Dysuria—Methotrexate—esophageal cancer	0.000335	0.00132	CcSEcCtD
Fluvoxamine—Paraesthesia—Cisplatin—esophageal cancer	0.000333	0.00132	CcSEcCtD
Fluvoxamine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000333	0.00132	CcSEcCtD
Fluvoxamine—Dyspnoea—Cisplatin—esophageal cancer	0.000331	0.00131	CcSEcCtD
Fluvoxamine—Flatulence—Capecitabine—esophageal cancer	0.00033	0.00131	CcSEcCtD
Fluvoxamine—Erectile dysfunction—Methotrexate—esophageal cancer	0.00033	0.0013	CcSEcCtD
Fluvoxamine—Dysgeusia—Capecitabine—esophageal cancer	0.000328	0.0013	CcSEcCtD
Fluvoxamine—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000327	0.00129	CcSEcCtD
Fluvoxamine—Back pain—Capecitabine—esophageal cancer	0.000324	0.00128	CcSEcCtD
Fluvoxamine—Decreased appetite—Cisplatin—esophageal cancer	0.000323	0.00128	CcSEcCtD
Fluvoxamine—Muscle spasms—Capecitabine—esophageal cancer	0.000322	0.00127	CcSEcCtD
Fluvoxamine—Pneumonia—Methotrexate—esophageal cancer	0.000321	0.00127	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00032	0.00127	CcSEcCtD
Fluvoxamine—Drowsiness—Methotrexate—esophageal cancer	0.000319	0.00126	CcSEcCtD
Fluvoxamine—Depression—Methotrexate—esophageal cancer	0.000318	0.00126	CcSEcCtD
Fluvoxamine—Pain—Cisplatin—esophageal cancer	0.000317	0.00125	CcSEcCtD
Fluvoxamine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000317	0.00125	CcSEcCtD
Fluvoxamine—Vision blurred—Capecitabine—esophageal cancer	0.000316	0.00125	CcSEcCtD
Fluvoxamine—Tremor—Capecitabine—esophageal cancer	0.000314	0.00124	CcSEcCtD
Fluvoxamine—Renal failure—Methotrexate—esophageal cancer	0.000314	0.00124	CcSEcCtD
Fluvoxamine—Stomatitis—Methotrexate—esophageal cancer	0.000311	0.00123	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000311	0.00123	CcSEcCtD
Fluvoxamine—Conjunctivitis—Methotrexate—esophageal cancer	0.00031	0.00123	CcSEcCtD
Fluvoxamine—Anaemia—Capecitabine—esophageal cancer	0.00031	0.00122	CcSEcCtD
Fluvoxamine—Sweating—Methotrexate—esophageal cancer	0.000306	0.00121	CcSEcCtD
Fluvoxamine—Feeling abnormal—Cisplatin—esophageal cancer	0.000306	0.00121	CcSEcCtD
Fluvoxamine—Haematuria—Methotrexate—esophageal cancer	0.000305	0.0012	CcSEcCtD
Fluvoxamine—Malaise—Capecitabine—esophageal cancer	0.000302	0.00119	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000302	0.00119	CcSEcCtD
Fluvoxamine—Epistaxis—Methotrexate—esophageal cancer	0.000301	0.00119	CcSEcCtD
Fluvoxamine—Vertigo—Capecitabine—esophageal cancer	0.000301	0.00119	CcSEcCtD
Fluvoxamine—Syncope—Capecitabine—esophageal cancer	0.000301	0.00119	CcSEcCtD
Fluvoxamine—Leukopenia—Capecitabine—esophageal cancer	0.0003	0.00119	CcSEcCtD
Fluvoxamine—Agranulocytosis—Methotrexate—esophageal cancer	0.000298	0.00118	CcSEcCtD
Fluvoxamine—Palpitations—Capecitabine—esophageal cancer	0.000296	0.00117	CcSEcCtD
Fluvoxamine—Loss of consciousness—Capecitabine—esophageal cancer	0.000295	0.00116	CcSEcCtD
Fluvoxamine—Body temperature increased—Cisplatin—esophageal cancer	0.000293	0.00116	CcSEcCtD
Fluvoxamine—Cough—Capecitabine—esophageal cancer	0.000293	0.00116	CcSEcCtD
Fluvoxamine—Hypertension—Capecitabine—esophageal cancer	0.000289	0.00114	CcSEcCtD
Fluvoxamine—Haemoglobin—Methotrexate—esophageal cancer	0.000288	0.00114	CcSEcCtD
Fluvoxamine—Haemorrhage—Methotrexate—esophageal cancer	0.000287	0.00113	CcSEcCtD
Fluvoxamine—Hepatitis—Methotrexate—esophageal cancer	0.000287	0.00113	CcSEcCtD
Fluvoxamine—Chest pain—Capecitabine—esophageal cancer	0.000285	0.00113	CcSEcCtD
Fluvoxamine—Myalgia—Capecitabine—esophageal cancer	0.000285	0.00113	CcSEcCtD
Fluvoxamine—Arthralgia—Capecitabine—esophageal cancer	0.000285	0.00113	CcSEcCtD
Fluvoxamine—Pharyngitis—Methotrexate—esophageal cancer	0.000285	0.00112	CcSEcCtD
Fluvoxamine—Anxiety—Capecitabine—esophageal cancer	0.000284	0.00112	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Methotrexate—esophageal cancer	0.000283	0.00112	CcSEcCtD
Fluvoxamine—Discomfort—Capecitabine—esophageal cancer	0.000282	0.00111	CcSEcCtD
Fluvoxamine—Urethral disorder—Methotrexate—esophageal cancer	0.000281	0.00111	CcSEcCtD
Fluvoxamine—Dry mouth—Capecitabine—esophageal cancer	0.000279	0.0011	CcSEcCtD
Fluvoxamine—Visual impairment—Methotrexate—esophageal cancer	0.000276	0.00109	CcSEcCtD
Fluvoxamine—Confusional state—Capecitabine—esophageal cancer	0.000276	0.00109	CcSEcCtD
Fluvoxamine—Oedema—Capecitabine—esophageal cancer	0.000274	0.00108	CcSEcCtD
Fluvoxamine—Hypersensitivity—Cisplatin—esophageal cancer	0.000273	0.00108	CcSEcCtD
Fluvoxamine—Infection—Capecitabine—esophageal cancer	0.000272	0.00107	CcSEcCtD
Fluvoxamine—Erythema multiforme—Methotrexate—esophageal cancer	0.000271	0.00107	CcSEcCtD
Fluvoxamine—Shock—Capecitabine—esophageal cancer	0.000269	0.00106	CcSEcCtD
Fluvoxamine—Nervous system disorder—Capecitabine—esophageal cancer	0.000268	0.00106	CcSEcCtD
Fluvoxamine—Eye disorder—Methotrexate—esophageal cancer	0.000268	0.00106	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000268	0.00106	CcSEcCtD
Fluvoxamine—Tinnitus—Methotrexate—esophageal cancer	0.000267	0.00106	CcSEcCtD
Fluvoxamine—Tachycardia—Capecitabine—esophageal cancer	0.000267	0.00106	CcSEcCtD
Fluvoxamine—Asthenia—Cisplatin—esophageal cancer	0.000266	0.00105	CcSEcCtD
Fluvoxamine—Cardiac disorder—Methotrexate—esophageal cancer	0.000266	0.00105	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000265	0.00105	CcSEcCtD
Fluvoxamine—Anorexia—Capecitabine—esophageal cancer	0.000261	0.00103	CcSEcCtD
Fluvoxamine—Angiopathy—Methotrexate—esophageal cancer	0.00026	0.00103	CcSEcCtD
Fluvoxamine—Chills—Methotrexate—esophageal cancer	0.000257	0.00102	CcSEcCtD
Fluvoxamine—Hypotension—Capecitabine—esophageal cancer	0.000256	0.00101	CcSEcCtD
Fluvoxamine—Diarrhoea—Cisplatin—esophageal cancer	0.000254	0.001	CcSEcCtD
Fluvoxamine—Alopecia—Methotrexate—esophageal cancer	0.000253	0.001	CcSEcCtD
Fluvoxamine—Mental disorder—Methotrexate—esophageal cancer	0.000251	0.000993	CcSEcCtD
Fluvoxamine—Malnutrition—Methotrexate—esophageal cancer	0.00025	0.000986	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000249	0.000985	CcSEcCtD
Fluvoxamine—Insomnia—Capecitabine—esophageal cancer	0.000247	0.000978	CcSEcCtD
Fluvoxamine—Paraesthesia—Capecitabine—esophageal cancer	0.000246	0.000971	CcSEcCtD
Fluvoxamine—Dysgeusia—Methotrexate—esophageal cancer	0.000244	0.000966	CcSEcCtD
Fluvoxamine—Dyspnoea—Capecitabine—esophageal cancer	0.000244	0.000964	CcSEcCtD
Fluvoxamine—Back pain—Methotrexate—esophageal cancer	0.000241	0.000954	CcSEcCtD
Fluvoxamine—Dyspepsia—Capecitabine—esophageal cancer	0.000241	0.000952	CcSEcCtD
Fluvoxamine—Decreased appetite—Capecitabine—esophageal cancer	0.000238	0.00094	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000236	0.000933	CcSEcCtD
Fluvoxamine—Vomiting—Cisplatin—esophageal cancer	0.000236	0.000933	CcSEcCtD
Fluvoxamine—Fatigue—Capecitabine—esophageal cancer	0.000236	0.000932	CcSEcCtD
Fluvoxamine—Vision blurred—Methotrexate—esophageal cancer	0.000235	0.000929	CcSEcCtD
Fluvoxamine—Rash—Cisplatin—esophageal cancer	0.000234	0.000925	CcSEcCtD
Fluvoxamine—Pain—Capecitabine—esophageal cancer	0.000234	0.000925	CcSEcCtD
Fluvoxamine—Constipation—Capecitabine—esophageal cancer	0.000234	0.000925	CcSEcCtD
Fluvoxamine—Dermatitis—Cisplatin—esophageal cancer	0.000234	0.000924	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000232	0.000915	CcSEcCtD
Fluvoxamine—Anaemia—Methotrexate—esophageal cancer	0.000231	0.000912	CcSEcCtD
Fluvoxamine—Feeling abnormal—Capecitabine—esophageal cancer	0.000225	0.000891	CcSEcCtD
Fluvoxamine—Malaise—Methotrexate—esophageal cancer	0.000225	0.000889	CcSEcCtD
Fluvoxamine—Vertigo—Methotrexate—esophageal cancer	0.000224	0.000886	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000224	0.000884	CcSEcCtD
Fluvoxamine—Leukopenia—Methotrexate—esophageal cancer	0.000223	0.000883	CcSEcCtD
Fluvoxamine—Nausea—Cisplatin—esophageal cancer	0.00022	0.000871	CcSEcCtD
Fluvoxamine—Cough—Methotrexate—esophageal cancer	0.000218	0.000861	CcSEcCtD
Fluvoxamine—Urticaria—Capecitabine—esophageal cancer	0.000217	0.000859	CcSEcCtD
Fluvoxamine—Abdominal pain—Capecitabine—esophageal cancer	0.000216	0.000855	CcSEcCtD
Fluvoxamine—Body temperature increased—Capecitabine—esophageal cancer	0.000216	0.000855	CcSEcCtD
Fluvoxamine—Convulsion—Methotrexate—esophageal cancer	0.000216	0.000854	CcSEcCtD
Fluvoxamine—Arthralgia—Methotrexate—esophageal cancer	0.000212	0.00084	CcSEcCtD
Fluvoxamine—Chest pain—Methotrexate—esophageal cancer	0.000212	0.00084	CcSEcCtD
Fluvoxamine—Myalgia—Methotrexate—esophageal cancer	0.000212	0.00084	CcSEcCtD
Fluvoxamine—Discomfort—Methotrexate—esophageal cancer	0.00021	0.00083	CcSEcCtD
Fluvoxamine—Confusional state—Methotrexate—esophageal cancer	0.000205	0.000812	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000204	0.000805	CcSEcCtD
Fluvoxamine—Infection—Methotrexate—esophageal cancer	0.000202	0.0008	CcSEcCtD
Fluvoxamine—Hypersensitivity—Capecitabine—esophageal cancer	0.000202	0.000797	CcSEcCtD
Fluvoxamine—Nervous system disorder—Methotrexate—esophageal cancer	0.0002	0.000789	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000199	0.000788	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000197	0.000778	CcSEcCtD
Fluvoxamine—Asthenia—Capecitabine—esophageal cancer	0.000196	0.000776	CcSEcCtD
Fluvoxamine—Anorexia—Methotrexate—esophageal cancer	0.000194	0.000767	CcSEcCtD
Fluvoxamine—Pruritus—Capecitabine—esophageal cancer	0.000194	0.000765	CcSEcCtD
Fluvoxamine—Hypotension—Methotrexate—esophageal cancer	0.00019	0.000752	CcSEcCtD
Fluvoxamine—Diarrhoea—Capecitabine—esophageal cancer	0.000187	0.00074	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000186	0.000733	CcSEcCtD
Fluvoxamine—Insomnia—Methotrexate—esophageal cancer	0.000184	0.000728	CcSEcCtD
Fluvoxamine—Paraesthesia—Methotrexate—esophageal cancer	0.000183	0.000723	CcSEcCtD
Fluvoxamine—Dyspnoea—Methotrexate—esophageal cancer	0.000182	0.000718	CcSEcCtD
Fluvoxamine—Somnolence—Methotrexate—esophageal cancer	0.000181	0.000716	CcSEcCtD
Fluvoxamine—Dizziness—Capecitabine—esophageal cancer	0.000181	0.000715	CcSEcCtD
Fluvoxamine—Dyspepsia—Methotrexate—esophageal cancer	0.000179	0.000708	CcSEcCtD
Fluvoxamine—Decreased appetite—Methotrexate—esophageal cancer	0.000177	0.0007	CcSEcCtD
Fluvoxamine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000176	0.000695	CcSEcCtD
Fluvoxamine—Fatigue—Methotrexate—esophageal cancer	0.000176	0.000694	CcSEcCtD
Fluvoxamine—Pain—Methotrexate—esophageal cancer	0.000174	0.000688	CcSEcCtD
Fluvoxamine—Vomiting—Capecitabine—esophageal cancer	0.000174	0.000687	CcSEcCtD
Fluvoxamine—Rash—Capecitabine—esophageal cancer	0.000173	0.000682	CcSEcCtD
Fluvoxamine—Dermatitis—Capecitabine—esophageal cancer	0.000172	0.000681	CcSEcCtD
Fluvoxamine—Headache—Capecitabine—esophageal cancer	0.000171	0.000677	CcSEcCtD
Fluvoxamine—Feeling abnormal—Methotrexate—esophageal cancer	0.000168	0.000663	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000167	0.000658	CcSEcCtD
Fluvoxamine—Nausea—Capecitabine—esophageal cancer	0.000163	0.000642	CcSEcCtD
Fluvoxamine—Urticaria—Methotrexate—esophageal cancer	0.000162	0.000639	CcSEcCtD
Fluvoxamine—Body temperature increased—Methotrexate—esophageal cancer	0.000161	0.000636	CcSEcCtD
Fluvoxamine—Abdominal pain—Methotrexate—esophageal cancer	0.000161	0.000636	CcSEcCtD
Fluvoxamine—Hypersensitivity—Methotrexate—esophageal cancer	0.00015	0.000593	CcSEcCtD
Fluvoxamine—Asthenia—Methotrexate—esophageal cancer	0.000146	0.000577	CcSEcCtD
Fluvoxamine—Pruritus—Methotrexate—esophageal cancer	0.000144	0.000569	CcSEcCtD
Fluvoxamine—Diarrhoea—Methotrexate—esophageal cancer	0.000139	0.000551	CcSEcCtD
Fluvoxamine—Dizziness—Methotrexate—esophageal cancer	0.000135	0.000532	CcSEcCtD
Fluvoxamine—Vomiting—Methotrexate—esophageal cancer	0.00013	0.000512	CcSEcCtD
Fluvoxamine—Rash—Methotrexate—esophageal cancer	0.000128	0.000507	CcSEcCtD
Fluvoxamine—Dermatitis—Methotrexate—esophageal cancer	0.000128	0.000507	CcSEcCtD
Fluvoxamine—Headache—Methotrexate—esophageal cancer	0.000128	0.000504	CcSEcCtD
Fluvoxamine—Nausea—Methotrexate—esophageal cancer	0.000121	0.000478	CcSEcCtD
Fluvoxamine—CYP1A1—Metabolism—GNG7—esophageal cancer	2.8e-05	0.000126	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	2.79e-05	0.000126	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ALDH2—esophageal cancer	2.78e-05	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ADH1B—esophageal cancer	2.78e-05	0.000125	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ALDH2—esophageal cancer	2.78e-05	0.000125	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP26A1—esophageal cancer	2.76e-05	0.000125	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALOX15—esophageal cancer	2.76e-05	0.000124	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP19A1—esophageal cancer	2.74e-05	0.000123	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	2.73e-05	0.000123	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ADH7—esophageal cancer	2.71e-05	0.000122	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PLCE1—esophageal cancer	2.71e-05	0.000122	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—GSTT1—esophageal cancer	2.7e-05	0.000122	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALOX15—esophageal cancer	2.69e-05	0.000121	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—TYMP—esophageal cancer	2.68e-05	0.000121	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	2.67e-05	0.000121	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP2A6—esophageal cancer	2.67e-05	0.00012	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—TYMP—esophageal cancer	2.65e-05	0.00012	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—GSTT1—esophageal cancer	2.65e-05	0.000119	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—GSTT1—esophageal cancer	2.64e-05	0.000119	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTO1—esophageal cancer	2.63e-05	0.000119	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—TPI1—esophageal cancer	2.63e-05	0.000119	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ALDH2—esophageal cancer	2.62e-05	0.000118	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP2A6—esophageal cancer	2.61e-05	0.000118	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP2A6—esophageal cancer	2.61e-05	0.000118	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	2.6e-05	0.000117	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP26A1—esophageal cancer	2.58e-05	0.000116	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—TPI1—esophageal cancer	2.57e-05	0.000116	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTO1—esophageal cancer	2.57e-05	0.000116	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALOX15—esophageal cancer	2.54e-05	0.000114	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ENO1—esophageal cancer	2.53e-05	0.000114	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS1—esophageal cancer	2.53e-05	0.000114	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALDOB—esophageal cancer	2.52e-05	0.000114	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALOX15—esophageal cancer	2.52e-05	0.000113	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—HMOX1—esophageal cancer	2.5e-05	0.000113	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—GSTT1—esophageal cancer	2.49e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PSME2—esophageal cancer	2.49e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PSME1—esophageal cancer	2.49e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ENO1—esophageal cancer	2.48e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS1—esophageal cancer	2.48e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS1—esophageal cancer	2.47e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ENO1—esophageal cancer	2.47e-05	0.000112	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP2A6—esophageal cancer	2.47e-05	0.000111	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALDOB—esophageal cancer	2.46e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CA1—esophageal cancer	2.46e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	2.46e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.46e-05	0.000111	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PSME1—esophageal cancer	2.44e-05	0.00011	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PSME2—esophageal cancer	2.44e-05	0.00011	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PSME1—esophageal cancer	2.44e-05	0.00011	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PSME2—esophageal cancer	2.44e-05	0.00011	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GAPDH—esophageal cancer	2.43e-05	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTO1—esophageal cancer	2.42e-05	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—TPI1—esophageal cancer	2.42e-05	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CRABP1—esophageal cancer	2.41e-05	0.000109	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—TPI1—esophageal cancer	2.4e-05	0.000108	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTO1—esophageal cancer	2.4e-05	0.000108	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ABCB1—esophageal cancer	2.4e-05	0.000108	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ADH1B—esophageal cancer	2.37e-05	0.000107	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GAPDH—esophageal cancer	2.37e-05	0.000107	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	2.37e-05	0.000107	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CRABP1—esophageal cancer	2.35e-05	0.000106	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ENO1—esophageal cancer	2.34e-05	0.000105	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS1—esophageal cancer	2.34e-05	0.000105	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALDOB—esophageal cancer	2.32e-05	0.000105	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PSME2—esophageal cancer	2.3e-05	0.000104	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PSME1—esophageal cancer	2.3e-05	0.000104	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALDOB—esophageal cancer	2.3e-05	0.000104	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GNG7—esophageal cancer	2.29e-05	0.000103	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	2.29e-05	0.000103	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—TYMP—esophageal cancer	2.27e-05	0.000102	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CA2—esophageal cancer	2.25e-05	0.000101	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GNG7—esophageal cancer	2.23e-05	0.000101	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GAPDH—esophageal cancer	2.23e-05	0.000101	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GAPDH—esophageal cancer	2.21e-05	9.98e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CRABP1—esophageal cancer	2.21e-05	9.98e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	2.21e-05	9.94e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CRABP1—esophageal cancer	2.19e-05	9.89e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP1B1—esophageal cancer	2.15e-05	9.7e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALOX15—esophageal cancer	2.15e-05	9.69e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ALDH2—esophageal cancer	2.15e-05	9.67e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP1B1—esophageal cancer	2.11e-05	9.5e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GNG7—esophageal cancer	2.11e-05	9.49e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP1B1—esophageal cancer	2.1e-05	9.48e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ALDH2—esophageal cancer	2.09e-05	9.44e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PLCE1—esophageal cancer	2.09e-05	9.41e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ADH7—esophageal cancer	2.09e-05	9.41e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GNG7—esophageal cancer	2.09e-05	9.41e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTO1—esophageal cancer	2.05e-05	9.24e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—TPI1—esophageal cancer	2.05e-05	9.24e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—GSTT1—esophageal cancer	2.04e-05	9.2e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP19A1—esophageal cancer	2.02e-05	9.12e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP2A6—esophageal cancer	2.02e-05	9.09e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.01e-05	9.06e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.01e-05	9.06e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—GSTT1—esophageal cancer	1.99e-05	8.98e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP1B1—esophageal cancer	1.99e-05	8.96e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP19A1—esophageal cancer	1.98e-05	8.93e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP19A1—esophageal cancer	1.98e-05	8.91e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ALDH2—esophageal cancer	1.97e-05	8.9e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP2A6—esophageal cancer	1.97e-05	8.88e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALDOB—esophageal cancer	1.97e-05	8.86e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ALDH2—esophageal cancer	1.96e-05	8.82e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ENO1—esophageal cancer	1.91e-05	8.62e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS1—esophageal cancer	1.91e-05	8.62e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GAPDH—esophageal cancer	1.89e-05	8.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PSME2—esophageal cancer	1.88e-05	8.49e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PSME1—esophageal cancer	1.88e-05	8.49e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—GSTT1—esophageal cancer	1.88e-05	8.46e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CRABP1—esophageal cancer	1.88e-05	8.46e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP19A1—esophageal cancer	1.87e-05	8.42e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ENO1—esophageal cancer	1.87e-05	8.41e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS1—esophageal cancer	1.87e-05	8.41e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.86e-05	8.41e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—GSTT1—esophageal cancer	1.86e-05	8.39e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	1.86e-05	8.36e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—HMOX1—esophageal cancer	1.85e-05	8.32e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	1.84e-05	8.29e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PSME2—esophageal cancer	1.84e-05	8.29e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PSME1—esophageal cancer	1.84e-05	8.29e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.83e-05	8.26e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ADH1B—esophageal cancer	1.83e-05	8.25e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—HMOX1—esophageal cancer	1.81e-05	8.15e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—HMOX1—esophageal cancer	1.8e-05	8.13e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GNG7—esophageal cancer	1.78e-05	8.04e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ABCB1—esophageal cancer	1.77e-05	7.99e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ENO1—esophageal cancer	1.76e-05	7.93e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS1—esophageal cancer	1.76e-05	7.93e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TYMP—esophageal cancer	1.75e-05	7.89e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ENO1—esophageal cancer	1.74e-05	7.86e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS1—esophageal cancer	1.74e-05	7.86e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ABCB1—esophageal cancer	1.74e-05	7.82e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PSME1—esophageal cancer	1.73e-05	7.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PSME2—esophageal cancer	1.73e-05	7.81e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ABCB1—esophageal cancer	1.73e-05	7.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PSME1—esophageal cancer	1.72e-05	7.75e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PSME2—esophageal cancer	1.72e-05	7.75e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—HMOX1—esophageal cancer	1.7e-05	7.68e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	1.7e-05	7.67e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.67e-05	7.54e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ALDH2—esophageal cancer	1.67e-05	7.54e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALOX15—esophageal cancer	1.66e-05	7.48e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.65e-05	7.42e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ABCB1—esophageal cancer	1.64e-05	7.38e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP1B1—esophageal cancer	1.63e-05	7.33e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CREBBP—esophageal cancer	1.6e-05	7.22e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—GSTT1—esophageal cancer	1.59e-05	7.17e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP1B1—esophageal cancer	1.59e-05	7.15e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTO1—esophageal cancer	1.58e-05	7.13e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—TPI1—esophageal cancer	1.58e-05	7.13e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	1.57e-05	7.09e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	1.57e-05	7.06e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP19A1—esophageal cancer	1.53e-05	6.89e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALDOB—esophageal cancer	1.52e-05	6.84e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.5e-05	6.76e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	1.5e-05	6.74e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.49e-05	6.73e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS1—esophageal cancer	1.49e-05	6.72e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ENO1—esophageal cancer	1.49e-05	6.72e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	1.48e-05	6.68e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PSME2—esophageal cancer	1.47e-05	6.62e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PSME1—esophageal cancer	1.47e-05	6.62e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GAPDH—esophageal cancer	1.46e-05	6.58e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CRABP1—esophageal cancer	1.45e-05	6.53e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—NOS3—esophageal cancer	1.43e-05	6.46e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	1.41e-05	6.34e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—HMOX1—esophageal cancer	1.4e-05	6.29e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	1.39e-05	6.28e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GNG7—esophageal cancer	1.38e-05	6.21e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.37e-05	6.17e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—HMOX1—esophageal cancer	1.36e-05	6.14e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ABCB1—esophageal cancer	1.34e-05	6.04e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PTGS2—esophageal cancer	1.31e-05	5.91e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ALDH2—esophageal cancer	1.29e-05	5.82e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—HMOX1—esophageal cancer	1.28e-05	5.78e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.28e-05	5.78e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—HMOX1—esophageal cancer	1.27e-05	5.73e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	1.27e-05	5.71e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.25e-05	5.63e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.24e-05	5.58e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ABCB1—esophageal cancer	1.23e-05	5.55e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—GSTT1—esophageal cancer	1.23e-05	5.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ABCB1—esophageal cancer	1.22e-05	5.5e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	1.21e-05	5.47e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	1.19e-05	5.37e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CREBBP—esophageal cancer	1.18e-05	5.34e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CREBBP—esophageal cancer	1.16e-05	5.23e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CREBBP—esophageal cancer	1.16e-05	5.22e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ENO1—esophageal cancer	1.15e-05	5.18e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS1—esophageal cancer	1.15e-05	5.18e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PSME2—esophageal cancer	1.13e-05	5.11e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PSME1—esophageal cancer	1.13e-05	5.11e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CREBBP—esophageal cancer	1.09e-05	4.93e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—EP300—esophageal cancer	1.09e-05	4.92e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—HMOX1—esophageal cancer	1.09e-05	4.9e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.07e-05	4.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—NOS3—esophageal cancer	1.06e-05	4.78e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ABCB1—esophageal cancer	1.04e-05	4.7e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—NOS3—esophageal cancer	1.04e-05	4.68e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—NOS3—esophageal cancer	1.04e-05	4.67e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.01e-05	4.56e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—NOS3—esophageal cancer	9.79e-06	4.41e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	9.78e-06	4.41e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PTGS2—esophageal cancer	9.7e-06	4.37e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PTGS2—esophageal cancer	9.5e-06	4.28e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PTGS2—esophageal cancer	9.48e-06	4.27e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	9.23e-06	4.16e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	9.19e-06	4.14e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PTGS2—esophageal cancer	8.96e-06	4.04e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CREBBP—esophageal cancer	8.95e-06	4.03e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CREBBP—esophageal cancer	8.73e-06	3.94e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—HMOX1—esophageal cancer	8.39e-06	3.78e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CREBBP—esophageal cancer	8.23e-06	3.71e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—CREBBP—esophageal cancer	8.16e-06	3.68e-05	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CA—esophageal cancer	8.07e-06	3.64e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—EP300—esophageal cancer	8.07e-06	3.64e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ABCB1—esophageal cancer	8.05e-06	3.63e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—NOS3—esophageal cancer	8.01e-06	3.61e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—EP300—esophageal cancer	7.9e-06	3.56e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	7.89e-06	3.56e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—EP300—esophageal cancer	7.88e-06	3.55e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—NOS3—esophageal cancer	7.82e-06	3.53e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—EP300—esophageal cancer	7.45e-06	3.36e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—NOS3—esophageal cancer	7.37e-06	3.32e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PTGS2—esophageal cancer	7.33e-06	3.3e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—NOS3—esophageal cancer	7.31e-06	3.29e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PTGS2—esophageal cancer	7.15e-06	3.22e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CREBBP—esophageal cancer	6.97e-06	3.14e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PTGS2—esophageal cancer	6.74e-06	3.04e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PTGS2—esophageal cancer	6.68e-06	3.01e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—NOS3—esophageal cancer	6.24e-06	2.81e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—EP300—esophageal cancer	6.09e-06	2.75e-05	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CA—esophageal cancer	5.97e-06	2.69e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—EP300—esophageal cancer	5.95e-06	2.68e-05	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CA—esophageal cancer	5.84e-06	2.63e-05	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CA—esophageal cancer	5.83e-06	2.63e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PTGS2—esophageal cancer	5.71e-06	2.57e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—EP300—esophageal cancer	5.61e-06	2.53e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—EP300—esophageal cancer	5.56e-06	2.51e-05	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CA—esophageal cancer	5.51e-06	2.48e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CREBBP—esophageal cancer	5.38e-06	2.43e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—NOS3—esophageal cancer	4.82e-06	2.17e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—EP300—esophageal cancer	4.75e-06	2.14e-05	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CA—esophageal cancer	4.51e-06	2.03e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PTGS2—esophageal cancer	4.41e-06	1.99e-05	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CA—esophageal cancer	4.4e-06	1.98e-05	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	4.15e-06	1.87e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	4.11e-06	1.85e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—EP300—esophageal cancer	3.67e-06	1.65e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	3.51e-06	1.58e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	2.71e-06	1.22e-05	CbGpPWpGaD
